Quantcast

Latest Treatment of schizophrenia Stories

2008-10-09 18:00:12

Alkermes, Inc. (NASDAQ: ALKS) today announced that patients with schizophrenia now have a new administration option for RISPERDAL(R) CONSTA(R) ((risperidone) Long-Acting Injection). The U.S. Food and Drug Administration (FDA) has approved a new injection site, the deltoid muscle in the arm, for RISPERDAL CONSTA for the treatment of patients with schizophrenia. RISPERDAL CONSTA was previously approved as a gluteal injection only. "RISPERDAL CONSTA serves an important role in the treatment of...

2008-10-07 09:00:55

INDIANAPOLIS, Ind., Oct. 7 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that it has resolved a multi-state investigation involving 32 states and the District of Columbia (DC) related to the sales, marketing and promotion of its antipsychotic medication Zyprexa(R) (olanzapine). "We believe all of the parties involved share an interest in putting this dispute behind us," said Robert A. Armitage, Lilly's senior vice president and general counsel. "From our standpoint, it's...

2008-09-26 06:00:12

INDIANAPOLIS, Sept. 26 /PRNewswire-FirstCall/ -- The Committee for Medicinal Products for Human Use (CHMP) has recommended European approval of Olanzapine Long-acting Injection (LAI), known in Europe by the trade name Zypadhera(TM), for maintenance treatment of adult patients with schizophrenia sufficiently stabilized during acute treatment with oral olanzapine, Eli Lilly and Company (LLY) announced today. The CHMP's positive opinion is now referred for final action to the European...

2008-09-19 09:00:40

The newer drugs for treating schizophrenia have come under such a cloud that it's no surprise to learn of another setback: They work no better than an older, less expensive drug in children and adolescents . It is another disturbing example of how aggressive marketing can propel drugs to blockbuster sales even though they are no more effective, and possibly more risky, than older versions. A U.S. government-supported study delivered the bad news this week about Zyprexa, made by Eli...

2008-09-15 09:00:58

Lundbeck has announced that the FDA has completed the initial check for completeness and accepted the new drug application on Serdolect for the treatment of schizophrenia for review. Lundbeck said that this is the first new drug application (NDA) submitted in the US by the company, and it follows the launch of Serdolect in Europe, South and Central America, Asia and the Middle East. According to the company, Serdolect is an effective antipsychotic drug for the treatment of schizophrenia...

2008-09-02 09:00:07

BARCELONA, Spain, Sept. 2 /PRNewswire-FirstCall/ -- Final results from a 24-week study presented today at a major medical meeting in Barcelona suggest that investigational olanzapine long-acting injection (LAI) therapeutic doses showed a maintenance of treatment benefit for up to six months. A review of pooled safety data from all olanzapine LAI clinical trials was also presented at the meeting. Olanzapine LAI is an investigational formulation that combines Zyprexa(R) (olanzapine), an...

2008-07-29 09:01:15

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a patent application that would provide broad coverage for a pharmaceutical composition of zonisamide in combination with a series of marketed atypical antipsychotics. Orexigen is currently evaluating a combination product, OREX-003, for the treatment of schizophrenia that it hopes would minimize the potential...

2008-07-24 09:00:25

Alkermes, Inc. (NASDAQ: ALKS) today announced that its partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), submitted a supplemental New Drug Application (sNDA) for RISPERDAL(R) CONSTA(R) ((risperidone) Long-Acting Injection) to the U.S. Food and Drug Administration (FDA) for approval as monotherapy in the maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in adults. Bipolar disorder is a brain disorder...

2008-07-10 09:01:29

WALTHAM, Mass., July 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Janssen's Risperdal continues to be the leading first-line antipsychotic in the treatment of schizophrenia even though generic forms of the drug are already available and will dramatically affect physicians' prescribing habits due to new formulary controls on branded therapies. Although a large number of schizophrenia...

2008-07-01 12:01:08

The U.S. Food and Drug Administration says it's approved the first generic versions of Risperdal tablets for certain psychiatric disorders. The FDA said Risperdal (risperidone) is an anti-psychotic drug used for the treatment of schizophrenia, bipolar disorder and other psychiatric conditions. Varying strengths of risperidone tablets, manufactured by TEVA Pharmaceuticals USA, have been approved, although the labeling of the generic risperidone might differ from that of Risperdal because...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related